Birmarcker family tightens grip on Brazil's Profarma in $62.7M buyout
What's the deal? US drug distributor CencoraDealroom has a profile for this one. Try Dealroom → has agreed to sell its 38.18% stake in Brazilian pharmaceutical group ProfarmaDealroom has a profile for this one. Try Dealroom → to BTC Participações, an affiliate of BMK Participações, the holding company controlled by the founding Birmarcker family. The transaction is valued at roughly 350 million reais (about $62.7 million). The deal increases the family's grip on Profarma, which distributes medicines and owns the d1000 drugstore chain.
Why now? The sale ends a shareholder partnership that began in 2014, when Cencora — then AmerisourceBergen — took a 19.9% stake through a 186.8 million-real capital increase. That holding grew to 38.18% by 2018. The agreement also terminates the shareholders' pact between BMK and Cencora's BPL Brazil Holding Company, first signed in June 2014.
Who are they? Profarma, founded in 1961 in Rio de Janeiro by Manoel Birmarcker, runs three main units: drug distribution, the d1000 retail chain, and a specialties arm led by 4BioDealroom has a profile for this one. Try Dealroom →. The d1000 chain operates brands including Drogasmil, Farmalife, Drogarias Tamoio, and Drogaria Rosário, with 312 stores as of June 2026.
What's the endgame? With Cencora's exit, the Birmarcker family consolidates control of the distributor. Sammy Birmarcker, chief executive officer and vice-chairman, joined the company in 1986 after working across logistics, purchasing, sales, and marketing. The move follows Profarma's May 2026 acquisition of specialty-drug firm 4Bio from RD Saúde for 600 million reais.
What could go wrong? The deal still needs clearance from Brazil's antitrust authority, the Conselho Administrativo de Defesa Econômica, and must meet other contractual conditions. The $62.7 million figure is an estimate based on Profarma's market price on the B3 exchange, not necessarily the amount agreed between the parties.
The signal: The transaction is less about sector consolidation than about governance and aligning control under one family. It lands in a pharmaceutical retail market that is expanding but increasingly crowded, with large chains opening stores and growing online sales, and Mercado Livre entering fast medicine delivery. On its own, the deal does not change d1000's operations or resolve the group's competitive challenges.
Read more: investnews.com.br
Image credit: U.S. Department of Agriculture